Eli Lilly has received US regulatory approval for its once-daily oral GLP-1 receptor agonist, Foundayo (orforglipron), for chronic weight management in adults with obesity or overweight with weight-related comorbidities. In the pivotal ATTAIN-1 trial, participants taking the highest dose lost an average of 12.4% of their body weight compared to 0.9% in the placebo group. The drug also improved key cardiometabolic risk markers, including waist circumference and blood pressure.

Lilly plans to launch the drug in the US market through its LillyDirect platform and retail pharmacies, with a list price starting at USD 149 per month for out-of-pocket patients. The company has submitted regulatory applications for orforglipron in over 40 countries, including China, for weight management and type 2 diabetes (T2D).

PharmCube's NextBiopharm® database shows that orforglipron is undergoing Phase III trials in 11 additional indications. Click here to request a free trial for NextBiopharm®.